Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib
Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib
复制标题
DOI：
10.1093/annonc/mdm409
复制
发表时间：
2007-01-01
影响因子：
50.5
通讯作者：
Bello, C.
中科院分区：
文献类型：
--
作者：
Deprimo, S. E.;Bello, C.
评估针对肿瘤病理学中特定生物途径的新药临床活性的传统方法可能无法提供与临床相关结果（例如患者生存或无进展疾病）的相关性，因此应探索新的替代方法。生物标志物可以协助评估，一旦得到验证，就可以作为临床活动的替代品。血管生成是众所周知的与肿瘤生长和转移有关的过程，是当今用于治疗癌症的几种药物的目标。用于检测参与血管生成的蛋白质的实验室测定和新兴的成像方法已经提供了迄今为止该领域的大量生物标志物数据，并且已经证实了抗血管生成策略的生化基础的各个方面。本次研讨会文章将简要概述几种不同肿瘤类型的生物标志物数据，并讨论舒尼替尼和其他抗血管生成药物对这些生物标志物的影响。讨论的替代生物标志物包括血液或尿液中发现的可溶性蛋白质、循环内皮细胞及其祖细胞以及非侵入性成像技术。
Conventional methods to assess the clinical activity of new agents that target specific biological pathways involved in tumour pathology may not provide correlation with clinically relevant outcomes such as patient survival or progression-free disease, and new and alternative methods should be explored. Biomarkers can assist in evaluation, and once validated, serve as a surrogate for clinical activity. Angiogenesis, a process well known to be involved in tumour growth and metastasis, is the target of several agents available today in the treatment of cancer. Laboratory assays used to detect proteins involved in angiogenesis and emerging imaging approaches have provided the bulk of the biomarker data to date in this area, and have already corroborated aspects of the biochemical basis of anti-angiogenic strategy. This symposium article will provide a brief overview of biomarker data in several different tumour types and discuss the effect that sunitinib and other anti-angiogenic agents have on these biomarkers. Surrogate biomarkers discussed include soluble proteins found in the blood or urine, circulating endothelial cells and their progenitors, and non-invasive imaging techniques.